Loading clinical trials...
Loading clinical trials...
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
TG Therapeutics, Inc.
Collaborators
NCT07417488 · Colorectal Cancer, Small Bowel Adenocarcinoma
NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more
NCT06160323 · Pancreatic Cancer Non-resectable, Tumor Pancreas, and more
NCT06728072 · Colorectal Cancer, CRC
NCT06307548 · Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, and more
TG Therapeutics Trial Site
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions